Individualised Therapy of Angiotensin Converting Enzyme (ACE) Inhibitors in Stable Coronary Artery Disease: Overview of the Primary Results of the PERindopril GENEtic Association (PERGENE) Study

Overview

Journal Neth Heart J

Specialty Cardiology & Vascular Diseases

Date 2011 Jun 21

PMID 21688035

Citations 4

Authors

J J Brugts

M P M De Maat

A H J Danser

E Boersma

M L Simoons

Affiliations

Soon will be listed here.

Abstract

In patients with stable coronary artery disease (CAD) without overt heart failure, ACE inhibitors are among the most commonly used drugs as these agents have been proven effective in reducing the risk of cardiovascular events. Considerable individual variations in the blood pressure response to ACE inhibitors are observed and as such heterogeneity in clinical treatment effect would be likely as well. Assessing the consistency of treatment benefit is essential for the rational and cost-effective prescription of ACE inhibitors. Information on heterogeneities in treatment effect between subgroups of patients could be used to develop an evidence-based guidance for the installation of ACE-inhibitor therapy. Obviously, therapy should only be applied in those patients who most likely will benefit. Attempts to develop such treatment guidance by using clinical characteristics have been unsuccessful. No heterogeneity in risk reduction by ACE inhibitors has been observed in relation to relevant clinical characteristics. A new approach to such 'guided-therapy' could be to integrate more patient-specific characteristics such as the patients' genetic information. If proven feasible, pharmacogenetic profiling could optimise patients' benefit of treatment and reduce unnecessary treatment of patients. Cardiovascular pharmacogenetic research of ACE inhibitors in coronary artery disease patients is in a formative stage and studies are limited. The PERGENE study is a large pharmacogenetic substudy of the EUROPA trial, aimed to assess the achievability of pharmacogenetic profiling. We provide an overview of the main results of the PERGENE study in terms of the genetic determinants of treatment benefit and blood pressure response. The main results of the PERGENE study show a pharmacogenetic profile related to the treatment benefit of perindopril identifying responders and non-responders to treatment.

Citing Articles

Correlation of insertion/deletion gene polymorphism with captopril effectiveness in Indonesian hypertensive patients.

Dewa A S Handani , Hermawan A, Ikawati Z Pharmacogenomics. 2024; 25(8-9):357-365.

PMID: 39069948 PMC: 11734884. DOI: 10.1080/14622416.2024.2375190.

An update on the pharmacogenetics of treating hypertension.

Fontana V, Luizon M, Sandrim V J Hum Hypertens. 2014; 29(5):283-91.

PMID: 25355012 DOI: 10.1038/jhh.2014.76.

Renin gene polymorphisms in bangladeshi hypertensive population.

Afruza R, Islam L, Banerjee S, Hassan M, Suzuki F, Nabi A J Genomics. 2014; 2:45-53.

PMID: 25057323 PMC: 4105428. DOI: 10.7150/jgen.5193.

Exercise training in chronic heart failure: mechanisms and therapies.

Piepoli M Neth Heart J. 2012; 21(2):85-90.

PMID: 23239451 PMC: 3547424. DOI: 10.1007/s12471-012-0367-6.

Genetics and tailored therapy in cardiovascular disease.

Doevendans P, Asselbergs F Neth Heart J. 2011; 20(1):3-4.

PMID: 22160993 PMC: 3247633. DOI: 10.1007/s12471-011-0231-0.

References

Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N . Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2008; 360(4):363-75. DOI: 10.1056/NEJMoa0808227. View

Merino V, Todiras M, Mori M, Sales V, Fonseca R, Saul V . Predisposition to atherosclerosis and aortic aneurysms in mice deficient in kinin B1 receptor and apolipoprotein E. J Mol Med (Berl). 2009; 87(10):953-63. DOI: 10.1007/s00109-009-0501-0. View

Ferrari R . Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert Rev Cardiovasc Ther. 2005; 3(1):15-29. DOI: 10.1586/14779072.3.1.15. View

Fox K, Alonso Garcia M, Ardissino D, Buszman P, Camici P, Crea F . Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006; 27(11):1341-81. DOI: 10.1093/eurheartj/ehl001. View

Brugts J, Danser A, de Maat M, den Uil C, Boersma E, Ferrari R . Pharmacogenetics of ACE inhibition in stable coronary artery disease: steps towards tailored drug therapy. Curr Opin Cardiol. 2008; 23(4):296-301. DOI: 10.1097/HCO.0b013e3283007ba6. View

Gainer J, Morrow J, Loveland A, King D, Brown N . Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med. 1998; 339(18):1285-92. DOI: 10.1056/NEJM199810293391804. View

Brugts J, Ninomiya T, Boersma E, Remme W, Bertrand M, Ferrari R . The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. Eur Heart J. 2009; 30(11):1385-94. DOI: 10.1093/eurheartj/ehp103. View

Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C, Woodward M . Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens. 2007; 25(5):951-8. DOI: 10.1097/HJH.0b013e3280bad9b4. View

Ceconi C, Fox K, Remme W, Simoons M, Bertrand M, Parrinello G . ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res. 2006; 73(1):237-46. DOI: 10.1016/j.cardiores.2006.10.021. View

10.

Dagenais G, Pogue J, Fox K, Simoons M, Yusuf S . Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet. 2006; 368(9535):581-8. DOI: 10.1016/S0140-6736(06)69201-5. View

11.

Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K . Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis. 1998; 140(2):199-270. DOI: 10.1016/s0021-9150(98)90209-x. View

12.

Pellacani A, Brunner H, Nussberger J . Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin Sci (Lond). 1994; 87(5):567-74. DOI: 10.1042/cs0870567. View

13.

Rodriguez-Granillo G, Vos J, Bruining N, Garcia-Garcia H, de Winter S, M R Ligthart J . Long-term effect of perindopril on coronary atherosclerosis progression (from the perindopril's prospective effect on coronary atherosclerosis by angiography and intravascular ultrasound evaluation [PERSPECTIVE] study). Am J Cardiol. 2007; 100(2):159-63. DOI: 10.1016/j.amjcard.2007.02.073. View

14.

Deckers J, Goedhart D, Boersma E, Briggs A, Bertrand M, Ferrari R . Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. Eur Heart J. 2006; 27(7):796-801. DOI: 10.1093/eurheartj/ehi809. View

15.

Torp-Pedersen C, Kober L . Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet. 1999; 354(9172):9-12. DOI: 10.1016/s0140-6736(98)09374-x. View

16.

Brugts J, den Uil C, Danser A, Boersma E . The renin-angiotensin-aldosterone system: approaches to guide angiotensin-converting enzyme inhibition in patients with coronary artery disease. Cardiology. 2008; 112(4):303-12. DOI: 10.1159/000159124. View

17.

. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993; 342(8875):821-8. View

18.

Xu J, Carretero O, Shesely E, Rhaleb N, Yang J, Bader M . The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice. Exp Physiol. 2008; 94(3):322-9. PMC: 2719971. DOI: 10.1113/expphysiol.2008.045583. View

19.

Marin-Castano M, Schanstra J, Neau E, Praddaude F, Pecher C, Girolami J . Induction of functional bradykinin b(1)-receptors in normotensive rats and mice under chronic Angiotensin-converting enzyme inhibitor treatment. Circulation. 2002; 105(5):627-32. DOI: 10.1161/hc0502.102965. View

20.

Pfeffer M, Braunwald E, Moye L, Basta L, Brown Jr E, Cuddy T . Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992; 327(10):669-77. DOI: 10.1056/NEJM199209033271001. View